Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

PARADIGM · Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes.

H2020Status: CLOSED1 March 201830 November 2020EU funding €4,498,931Call H2020-JTI-IMI2-2016-10-two-stage

PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE.PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures.PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come.PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.

Consortium · 36 organisations

coordinator

FORUM DES PATIENTS EUROPEENS

BE · €702,516

participant

EUROPEAN AIDS TREATMENT GROUP EV

DE · €381,750

participant

JANSSEN PHARMACEUTICA NV

BE

participant

VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV

DE

participant

H. LUNDBECK AS

DK

thirdParty

SYNERGIST SERVICES

BE

participant

MERCK SHARP & DOHME CORP

US

participant

F. HOFFMANN-LA ROCHE AG

CH

participant

THE SYNERGIST

BE · €543,829

participant

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

DE

participant

THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY

UK

participant

TEAMIT RESEARCH SL

ES · €73,903

participant

AGENZIA ITALIANA DEL FARMACO

IT · €50,000

participant

AMGEN LIMITED

UK

participant

GRUNENTHAL GMBH

DE

participant

BAYER AKTIENGESELLSCHAFT

DE

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €621,593

participant

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

FR

participant

HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL SOCIETY

CA

participant

NOVO NORDISK A/S

DK

participant

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

FR

participant

ELI LILLY AND COMPANY LTD

UK

participant

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

ES · €399,595

participant

ALEXION SERVICES EUROPE SPRL

BE

participant

ALZHEIMER EUROPE

LU · €248,500

participant

LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED

UK

participant

PFIZER LIMITED

UK

participant

FUNDACIO PRIVADA PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DEU

ES · €176,125

participant

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK

participant

STICHTING VU

NL · €458,438

participant

EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE

BE · €198,000

participant

UCB BIOPHARMA

BE

participant

EURORDIS - RARE DISEASES EUROPE

FR · €463,598

participant

NOVARTIS PHARMA AG

CH

participant

FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES

BE

participant

INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD

ES · €181,086

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.